Chinese biotech teams with Lilly on cardiometabolic diseases; Senate finance chair goes after BMS
Chinese biotech Abbisko Therapeutics is teaming up with Eli Lilly on a new collaboration.
The pair announced Monday they will partner on cardiometabolic diseases and go after an unnamed target, with Abbisko eligible for up to $258 million in milestones. Abbisko will handle primarily the discovery work with input from Lilly, after which Lilly will have the option to further develop and potentially bring the program to market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.